Emergent Biosolutions Inc (N:EBS)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 400 Professional Dr Ste 400
GAITHERSBURG MD 20879-3457
Tel: 1-240-6313280
Website: https://emergentbiosolutions.com
IR: See website
<
Key People
Fuad El-Hibri
Executive Chairman of the Board
Robert G. Kramer
President, Chief Executive Officer, Director
Richard S. Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Katherine Strei
Chief Human Resource Officer, Executive Vice President
Atul Saran
Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
Adam Havey
Executive Vice President - Business Operations
Business Overview
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Financial Overview
For the nine months ended 30 September 2019, Emergent Biosolutions Inc revenues increased 46% to $745.6M. Net income decreased 88% to $7.7M. Revenues reflect Product sales, net increase of 52% to $592.7M, Contracts and grants increase of 94% to $98.3M. Net income was offset by Research and development increase of 80% to $163.4M (expense), Amort Intangibles excl Goodwill in SGA increase from $11.7M to $43.9M (expense).
Employees: 1,705 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $3,945M as of Sep 30, 2019
Annual revenue (TTM): $1,016M as of Sep 30, 2019
EBITDA (TTM): $155.59M as of Sep 30, 2019
Net annual income (TTM): -$0.08M as of Sep 30, 2019
Free cash flow (TTM): -$181.49M as of Sep 30, 2019
Net Debt Last Fiscal Year: $684.20M as of Sep 30, 2019
Shares outstanding: 51,623,596 as of Oct 30, 2019
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization